Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2791-2800

  Jasek, Ewa ^a   Lis, Grzegorz J ^a   Jasińska, MaŁgorzata ^a   Jurkowska, Halina ^a   Litwin, Jan A ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Apoptosis; Etoposide; HDACi; HL60; Leukemia; Trichostatin A; U937 cells; Valproic acid

Indexed keywords

ETOPOSIDE; PROTEIN BCL 2; TRICHOSTATIN A; VALPROIC ACID;

APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CELL STRAIN U937; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CASPASE 7; DRUG SYNERGISM; ETOPOSIDE; HISTONE DEACETYLASE INHIBITORS; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; U937 CELLS; VALPROIC ACID;

EID: 84865699205     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Dokmanovic M, Clarke C and Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981- 989, 2007.
2. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006. (Pubitemid 44348499)
3. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H and Altucci L: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11: 77-84, 2005. (Pubitemid 40215841)
4. Frew AJ, Johnstone RW and Bolden JE: Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280: 125-133, 2009.
5. Rasheed W, Bishton M, Johnstone RW and Prince HM: Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 8: 413-432, 2008. (Pubitemid 351836289)
6. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678, 2005. (Pubitemid 40282724)
7. Lee JH, Choy ML, Ngo L, Foster SS and Marks PA: Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107: 14639-14644, 2010.
8. Yu WP, Scott SA and Dong WF: Induction of ID1 expression and apoptosis by the histone deacetylase inhibitor (trichostatin A) in human acute myeloid leukaemic cells. Cell Prolif 41: 86-97, 2008.
9. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG and Schuppan D: The histone-deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36: 233-240, 2002. (Pubitemid 34146430)
10. Li GC, Zhang X, Pan TJ, Chen Z and Ye ZQ: Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int J Urol 13: 581-586, 2006. (Pubitemid 43760424)
11. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG and Heinzel T: Valproic acid defines a novel class of HDAC inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
12. Blaheta RA and Cinatl J Jr.: Antitumor mechanisms of valproate: a novel role for an old drug. Medicinal Res Rev 22: 492-511, 2002.
13. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW and Koeffler HP: Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33: 53-61, 2005. (Pubitemid 40127644)
14. Morotti A, Cilloni D, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Pilatrino C, Guerrasio A, Taulli R, Bracco E, Pautasso M, Baraban D, Gottardi E and Saglio G: Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 106: 1188-1196, 2006.
15. Zhang X, Yashiro M, Ren J and Hirakawa K: Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16: 563-568, 2006.
16. Yoon CY, Park MJ, Lee JS, Lee SC, Oh JJ, Park H, Chung CW, Abdullajanov MM, Jeong SJ, Hong SK, Byun SS, Lee ES and Lee SE: The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin-resistant human bladder cancer cell line. J Urol 185: 1102-1111, 2011.
17. Jeon HG, Yoon CY, Yu JH, Park MJ, Lee JE, Jeong SJ, Hong SK, Byun SS and Lee SE: Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and AKT signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin a in human bladder cancer cells. J Urol 186: 2084-2093, 2011.
18. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM and Garcia-Manero G: Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108: 1174-1182, 2006. (Pubitemid 44232012)
19. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H and Garcia-Manero G: Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 29: 739-748, 2005. (Pubitemid 40779480)
20. ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W and Bremer E: The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 21: 248-252, 2007. (Pubitemid 46158116)
21. Siitonen T, Koistinen P and Savolainen ER: Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27 (Kip 1) in acute myeloblastic leukemia cells. Leuk Res 29: 1335-1342, 2005. (Pubitemid 41297646)
22. Hande KR: Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34: 1514-1521, 1998.
23. Wilstermann AM, Bender RP, Godfrey M, Choi S, Anklin C, Berkowitz DB, Osheroff N and Graves DE: Topoisomerase II-drug interaction domains: identification of substituents on etoposide that interact with the enzyme. Biochemistry 46: 8217-8225, 2007. (Pubitemid 47075961)
24. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C and Powell SN: BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 67: 7078-7081, 2007. (Pubitemid 47206532)
25. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D and Seto E: Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26: 349-353, 2000.
26. Kurz EU, Wilson SE, Leader KB, Sampey BP, Allan WP, Yalowich JC and Kroll DJ: The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1: 121-131, 2001.
27. Johnson CA, Padget K, Austin C and Turner BM: Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis J Biol Chem 276: 4539-4542, 2001.
28. Hauswald S, Duque-Afonso J, Wagner MM, Schertl FM, Lübbert M, Peschel C, Keller U and Licht T: Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 15: 3705-3715, 2009.
29. Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, Carlton D, Gojo I, Sausville EA and Ross DD: Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 15: 1698-1707, 2009.
30. Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H and Furukawa Y: Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs 25: 31-40, 2007. (Pubitemid 44657640)
31. Jasek E, Mirecka J and Litwin JA: Effect of differentiating agents (all-trans retinoic acid and phorbol 12-myristate 13-acetate) on drug sensitivity of HL60 and NB4 cells in vitro. Folia Histochem Cytobiol 46: 323-330, 2008.
32. Hori M, Nogami T, Itabashi M, Yoshimi F, Ono H and Koizumi S: Expression of Bcl-2 in human breast cancer: Correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis. Pathol Int 47: 757-762, 1997. (Pubitemid 27527755)
33. Jurkowska H, Placha W, Nagahara N and Wróbel M: The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines. Amino Acids 41: 151-158, 2011.
34. Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene 27: 6398-6406, 2008.
35. Brunelle JK and Letai A: Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122: 437-441, 2009.
36. Dos Santos Ferreira AC, Fernandes RA, Kwee JK and Klumb CE: Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through BIM up-regulation in Burkitt's lymphoma cells. J Cancer Res Clin Oncol 138: 317-325, 2012.
37. dos Santos MP, Schwartsmann G, Roesler R, Brunetto AL and Abujamra AL: Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leuk Res 33: 218-221, 2009.
38. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003. (Pubitemid 37413470)
39. Bangert A, Häcker S, Cristofanon S, Debatin KM and Fulda S: Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anticancer Drugs 22: 494-499, 2011.
40. Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, Carlton D, Gojo I, Sausville EA and Ross DD: Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 15: 1698-1707, 2009.
41. Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H and Furukawa Y: Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional antileukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs 25: 31-40, 2007. (Pubitemid 44657640)
42. Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, Giaccone G, Pommier Y, Bates SE and Varticovski L: Schedule-dependent synergy of histone deacetylase inhibitors with DNA-damaging agents in small cell lung cancer. Cell Cycle 10: 3119-3128, 2011.
43. Drexler HG and MacLeod RA: Leukemia-lymphoma cell lines as model systems for hematopoietic research. Ann Med 35: 404-412, 2003. (Pubitemid 37255463)